Polar Asset Management Partners Inc. Makes New Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Polar Asset Management Partners Inc. purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 3rd quarter, HoldingsChannel reports. The firm purchased 88,100 shares of the company’s stock, valued at approximately $2,071,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after purchasing an additional 140,833 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Tyra Biosciences by 32.8% during the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after buying an additional 14,352 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Tyra Biosciences by 12.3% in the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after acquiring an additional 2,574 shares during the period. American Century Companies Inc. grew its stake in shares of Tyra Biosciences by 582.9% in the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after acquiring an additional 145,346 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new position in Tyra Biosciences during the second quarter worth $3,047,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Tyra Biosciences

In other news, CEO Todd Harris sold 10,092 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96. Following the completion of the sale, the chief executive officer now owns 1,479,528 shares of the company’s stock, valued at approximately $35,701,010.64. This trade represents a 0.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Nina S. Kjellson sold 11,078 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total value of $179,131.26. Following the completion of the transaction, the director now directly owns 472,207 shares in the company, valued at $7,635,587.19. The trade was a 2.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 101,050 shares of company stock valued at $2,235,492. 15.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Piper Sandler started coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Oppenheimer raised their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Finally, HC Wainwright lowered their price objective on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.00.

Tyra Biosciences Stock Down 1.3 %

Shares of TYRA opened at $15.17 on Friday. The company has a 50-day moving average price of $19.45 and a two-hundred day moving average price of $19.71. The stock has a market cap of $767.60 million, a price-to-earnings ratio of -9.42 and a beta of 1.01. Tyra Biosciences, Inc. has a 12 month low of $11.24 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities research analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.